海翔药业
(002099)
| 流通市值：90.70亿 | | | 总市值：90.81亿 |
| 流通股本：16.17亿 | | | 总股本：16.19亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 1,536,642,734.63 | 1,022,822,870.11 | 486,496,687.33 | 1,860,693,572.54 |
| 营业总成本 | 1,604,601,272.78 | 1,076,138,645.96 | 494,767,487.53 | 1,897,235,398.52 |
| 其他经营收益 | | | | |
| 营业利润 | -121,183,317.88 | -69,456,835.49 | 25,459,221.62 | -80,025,705.83 |
| 利润总额 | -118,844,429.39 | -67,852,816.78 | 26,113,433.19 | -84,091,024.28 |
| 净利润 | -136,724,057.36 | -64,502,728.52 | 26,302,843.26 | -93,754,370.28 |
| 每股收益 | | | | |
| 其他综合收益 | 395,371.61 | 395,371.61 | - | 14,373,444.92 |
| 综合收益总额 | -136,328,685.75 | -64,107,356.91 | 26,302,843.26 | -79,380,925.36 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 2,402,142,800.14 | 2,578,958,608.22 | 2,429,852,996.23 | 2,832,616,084.92 |
| 非流动资产: | | | | |
| 非流动资产合计 | 4,492,084,524.96 | 4,556,973,655.57 | 4,616,784,633.52 | 4,500,487,702.63 |
| 资产总计 | 6,894,227,325.1 | 7,135,932,263.79 | 7,046,637,629.75 | 7,333,103,787.55 |
| 流动负债: | | | | |
| 流动负债合计 | 2,148,068,556.6 | 2,265,017,878.34 | 2,022,555,098.35 | 2,215,778,753.85 |
| 非流动负债: | | | | |
| 非流动负债合计 | 99,553,686.51 | 91,100,007.68 | 92,040,867.53 | 86,526,913.01 |
| 负债合计 | 2,247,622,243.11 | 2,356,117,886.02 | 2,114,595,965.88 | 2,302,305,666.86 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 4,656,002,365.46 | 4,789,084,990.58 | 4,940,991,071.15 | 5,039,603,956.64 |
| 股东权益合计 | 4,646,605,081.99 | 4,779,814,377.77 | 4,932,041,663.87 | 5,030,798,120.69 |
| 负债和股东权益合计 | 6,894,227,325.1 | 7,135,932,263.79 | 7,046,637,629.75 | 7,333,103,787.55 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,195,503,645.83 | 798,554,276.95 | 410,139,995.24 | 1,590,168,231.45 |
| 经营活动现金流出小计 | 1,230,775,120.13 | 760,544,637.37 | 463,105,503.52 | 1,649,846,600 |
| 经营活动产生的现金流量净额 | -35,271,474.3 | 38,009,639.58 | -52,965,508.28 | -59,678,368.55 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 88,825,158.29 | 34,249,957.46 | 11,702,045.46 | 464,786,527.29 |
| 投资活动现金流出小计 | 262,161,890.34 | 223,413,741.44 | 146,304,821.23 | 157,158,470.85 |
| 投资活动产生的现金流量净额 | -173,336,732.05 | -189,163,783.98 | -134,602,775.77 | 307,628,056.44 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 1,167,866,626.96 | 865,266,626.96 | 263,706,000 | 2,699,830,000 |
| 筹资活动现金流出小计 | 1,483,962,466.46 | 1,056,264,856.51 | 574,058,594.32 | 2,596,806,364.58 |
| 筹资活动产生的现金流量净额 | -316,095,839.5 | -190,998,229.55 | -310,352,594.32 | 103,023,635.42 |
| 汇率变动对现金及现金等价物的影响 | -33,405,165.84 | -27,887,080.29 | -17,351,551.77 | -29,127,288.64 |
| 现金及现金等价物净增加额 | -558,109,211.69 | -370,039,454.24 | -515,272,430.14 | 321,846,034.67 |
| 期末现金及现金等价物余额 | 699,865,140.4 | 887,934,897.85 | 742,701,921.95 | 1,257,974,352.09 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -370,039,454.24 | - | 321,846,034.67 |